Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis

Blood (2016) 128 (22): 646.

https://doi.org/10.1182/blood.V128.22.646.646

Published: 2016

Journal Articles

High-Dose Cytarabine (HiDAC) Improves the Cure Rate of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): Is It Better to be Given As Induction Therapy or As Consolidation Therapy?

Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, Joel Wight, MBBS, Kathryn Jackson, MBBS, Ashanka Mahilal Beligaswatte, BA, MBBS, MD FRACP, FRCPA, Jason P Butler, MBBS, MMedSc, FRACP, FRCPA, Glen Kennedy, MBBS, FRACP, FRCPA, Louisa Martin, MBBS, Ian D. Lewis, MBBS PhD FRACP FRCPA, Devendra Hiwase, MBBS, FRACP, FRCPA, MD PhD, Daniela Zantomio, FRACP, FRCPA, MBBS, Simon Z. He, MBBS,FRACP,FRCPA, Andrew Grigg, MBBS, MD FRACP, FRCPA, Kirk Morris, FRACP FRCPA MBBS, Peter Mollee, MBBS, MMedSc, FRACP, FRCPA, Paula Marlton, MBBS

Blood (2016) 128 (22): 3989.

https://doi.org/10.1182/blood.V128.22.3989.3989

Published: 2016

Journal Articles

Diagnosis of Amyloidosis Subtype By Laser-Capture Microdissection (LCM) and Tandem Mass Spectrometry (MS/MS) Proteomic Analysis

Peter Mollee, MBBS, MMedSc, FRACP, FRCPA, Patricia Renaut, MBBS, FRCPA, Samuel Boros, MBBS, FRCPA, Dorothy Loo, MSc, Michelle Hill, PhD BSc (Hon), BA

Blood (2015) 126 (23): 1779.

https://doi.org/10.1182/blood.V126.23.1779.1779

Published: 2015

Journal Articles

Clinical Relevance of Partial Response in the Marrow (PRm) after Failure of Frontline Induction Chemotherapy for Adults with Acute Myeloid Leukemia (AML)

Shaun Fleming, MBBS (Hons), FRACP, FRCPA, Doen Ming Ong, MBBS, Kathryn Jackson, MBBS, FRACP, FRCPA, Sharon Avery, MBBS (Hons), FRACP, FRCPA, Peter Mollee, MBBS, MMedSc, FRACP, FRCPA, Paula Marlton, MBBS, FRACP, FRCPA, Glen A Kennedy, MBBS, FRACP, FRCPA, Andrew Wei, MBBS, FRACP, FRCPA, PhD

Blood (2015) 126 (23): 2512.

https://doi.org/10.1182/blood.V126.23.2512.2512

Published: 2015

Journal Articles

Emergence of Fc-Gamma-Riib-Dominance Contributes to Resistance to Therapeutic Antibodies in Patients with Chronic Lymphocytic Leukaemia

Melinda Burgess, Sally Mapp, MBBS, PhD FRACP, FRCPA, Roberta Mazzieri, PhD, Jonathan Ellis, BSc, MSc, PhD, Catherine Cheung, Lynne Chambers, Stephen Mattarollo, BSc, PhD, Peter Mollee, MBBS, MMedSc, FRACP, FRCPA, Devinder Gill, MB FRCPath FRACP FRCPA, Nicholas Saunders, BSc, PhD

Blood (2015) 126 (23): 447.

https://doi.org/10.1182/blood.V126.23.447.447

Published: 2015

Journal Articles

Sequential Treatment with Rituximab Followed by CHOP Chemotherapy in Adult B-Cell Post-Transplant Lymphoproliferative Disorder (PTLD) - Establishing a New Standard of Care: Final Results From the Prospective International Multicenter PTLD-1 Trial

Ralf Trappe, MD, PhD, Stephan H.K. Oertel, MD, Veronique Leblond, MD, PhD, Peter Mollee, MBBS, MMedSc, Monica Sender, MD, Petra Reinke, MD, PhD, Ruth Neuhaus, MD, Hans Lehmkuhl, MD, PhD, Heinz A. Horst, MD, Gilles Andre Salles, MD, PhD, Franck Morschhauser, Arnaud Jaccard, MD, PhD, Thierry Lamy, MD, PhD, Malte Leithäuser, MD, Ioannis Anagnostopoulos, MD, PhD, Martine Raphael, MD, PhD, Hanno Riess, MD, PhD, Sylvain Choquet, MD

Blood (2011) 118 (21): 878.

https://doi.org/10.1182/blood.V118.21.878.878

Published: 2011

Journal Articles

Falsely Low Serum Free Light Chain Concentration in Patients with Monoclonal Light Chain Diseases.

Peter Mollee, MBBS, MMedSc, Jill Tate, BSc, Goce Dimeski, BSc, Devinder Gill, MBBS

Blood (2005) 106 (11): 5077.

https://doi.org/10.1182/blood.V106.11.5077.5077

Published: 2005

NARROW

A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis

High-Dose Cytarabine (HiDAC) Improves the Cure Rate of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): Is It Better to be Given As Induction Therapy or As Consolidation Therapy?

Diagnosis of Amyloidosis Subtype By Laser-Capture Microdissection (LCM) and Tandem Mass Spectrometry (MS/MS) Proteomic Analysis

Clinical Relevance of Partial Response in the Marrow (PRm) after Failure of Frontline Induction Chemotherapy for Adults with Acute Myeloid Leukemia (AML)

Emergence of Fc-Gamma-Riib-Dominance Contributes to Resistance to Therapeutic Antibodies in Patients with Chronic Lymphocytic Leukaemia

Sequential Treatment with Rituximab Followed by CHOP Chemotherapy in Adult B-Cell Post-Transplant Lymphoproliferative Disorder (PTLD) - Establishing a New Standard of Care: Final Results From the Prospective International Multicenter PTLD-1 Trial

Falsely Low Serum Free Light Chain Concentration in Patients with Monoclonal Light Chain Diseases.

Email alerts

ASH Publications

American Society of Hematology

A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis

High-Dose Cytarabine (HiDAC) Improves the Cure Rate of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): Is It Better to be Given As Induction Therapy or As Consolidation Therapy?

Diagnosis of Amyloidosis Subtype By Laser-Capture Microdissection (LCM) and Tandem Mass Spectrometry (MS/MS) Proteomic Analysis

Clinical Relevance of Partial Response in the Marrow (PRm) after Failure of Frontline Induction Chemotherapy for Adults with Acute Myeloid Leukemia (AML)

Emergence of Fc-Gamma-Riib-Dominance Contributes to Resistance to Therapeutic Antibodies in Patients with Chronic Lymphocytic Leukaemia

Sequential Treatment with Rituximab Followed by CHOP Chemotherapy in Adult B-Cell Post-Transplant Lymphoproliferative Disorder (PTLD) - Establishing a New Standard of Care: Final Results From the Prospective International Multicenter PTLD-1 Trial

Falsely Low Serum Free Light Chain Concentration in Patients with Monoclonal Light Chain Diseases.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only